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Abstract
Dystonia is a neurological disorder in which sustained muscle contractions induce twisting and repetitive movements or
abnormal posturing. DYT1 early-onset primary dystonia is the most common form of hereditary dystonia and is caused by
deletion of a glutamic acid residue (302/303) near the carboxyl-terminus of encoded torsinA. TorsinA is localized primarily
within the contiguous lumen of the endoplasmic reticulum (ER) and nuclear envelope (NE), and is hypothesized to function
as a molecular chaperone and an important regulator of the ER stress-signaling pathway, but how the mutation in torsinA
causes disease remains unclear. Multiple lines of evidence suggest that the clinical symptoms of dystonia result from
abnormalities in dopamine (DA) signaling, and possibly involving its down-stream effector adenylate cyclase that produces
the second messenger cyclic adenosine-39,5 9-monophosphate (cAMP). Here we find that mutation in torsinA induces ER
stress, and inhibits the cyclic adenosine-39,5 9-monophosphate (cAMP) response to the adenylate cyclase agonist forskolin.
Both defective mechanins are corrected by the small molecule 4-phenylbutyrate (4-PBA) that alleviates ER stress. Our results
link torsinA, the ER-stress-response, and cAMP-dependent signaling, and suggest 4-PBA could also be used in dystonia
treatment. Other pharmacological agents known to modulate the cAMP cascade, and ER stress may also be therapeutic in
dystonia patients and can be tested in the models described here, thus supplementing current efforts centered on the
dopamine pathway.
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Introduction
The DYT1 early-onset primary dystonia is the most severe form
of hereditary dystonia and is caused by a mutation in the gene,
TOR1A (DYT1), encoding torsinA protein [1]. Current treat-
ments include high dose anticholinergics, which are only partially
effective and can compromise learning and memory [2]. Another
available treatment for dystonia is deep brain stimulation (DBS),
which involves an implant of stimulating electrodes into the basal
ganglia [3]. Although DBS can be effective in treating some DYT1
dystonia patients, it is a neurosurgical procedure with concomitant
risks and high cost. The DYT1 dystonia-associated protein,
torsinA, is a ubiquitously expressed protein in many organs,
including the central nervous system (CNS). Intriguingly, in
patients with DYT1 dystonia, only the CNS is affected. The
clinical phenotype of dystonia is thought to result from decreased
function of torsinA causing defects in neuronal function, including
abnormal dopaminergic neurotransmission in the basal ganglia
[4]. However, the role of torsinA and the correlation between the
dysfunction caused by the mutation and the dystonic phenotype
remain unclear. Many studies at the biochemical, structural, and
cell biological levels have been performed in order to characterize
torsinA [5,6]. These studies, together with the generation of
several animal models [7–9], have contributed to the identification
of cellular compartments and pathways affected by mutant
torsinA, including the nuclear envelope (NE) [10,11], cytoskeleton
[12,13], cell migration [12,14], secretory pathway [15–18],
dopamine pathway [5,19–22], synaptic vesicle recycling [22],
endoplasmic reticulum (ER) stress [23,24], and endoplasmic
reticulum-associated degradation (ERAD) [24,25], where torsinA’s
function may be crucial for the cell homeostasis.
To define therapeutic pathways to target dystonia, it is
important to identify cellular processes affected in the brain.
Our studies with dystonia animal models and fibroblast cells from
DYT1 patients have implicated decreased intracellular levels of
cAMP in these DYT1 dystonia models when compared to
controls. Alterations of the second messenger cAMP affect normal
brain function such as in synapses, neuronal memory, and striatal
plasticity [26–28], and can also be found in several neurological
PLOS ONE | www.plosone.org 1 November 2014 | Volume 9 | Issue 11 | e110086diseases, such as in Fragile X [29,30], and in Huntington disease
[31,32]. In the cells, the concentration of cAMP is regulated by
adenylate cyclases (AC) and phosphodiesterases (PDEs), respec-
tively in its synthesis and its degradation [33].
Dopamine is the pathway most extensively studied in dystonia.
Genetic mutations of the GCH1 gene, which codes for guanosine
triphosphate cyclohydrolase I (GTPCH I) [34], the tyrosine
hydroxylase (TH) gene [35], and the guanine nucleotide binding
protein (GNAL) gene [36] are found in dystonia, and surprisingly
share a common mechanism associated with the cyclic cAMP/
PKA pathway. GCH1 and TH gene products participate in
dopamine synthesis in the presynaptic neurons and both genes are
regulated by cAMP [37–39]. GNAL gene encodes G a olf, a
stimulatory subunit for heterotrimeric G-protein complexes
(GPCR) [35]. Upon activation, G a olf stimulates the coupling
of some GPCR subtypes such as dopamine receptor D1R,
dopamine receptor D5DR, and adenosine receptor A2AR with
adenylate cyclase, resulting in the generation of cAMP, and
protein kinase A (PKA) activation [40].
Our previous studies suggest that the presence of torsinADE
somehow contributes to ER stress load [23,24]. We recently
obseved that our DYT1 dystonia cell models have increase ER
stress and reduced intracellular cAMP levels. While it is not clear
how the mutant torsinADE affects ER stress and cAMP
production, we find these defects are rescued by treatment with
4-phenylbutyrate (4- PBA), a small molecule that suppresses the
ER stress response to misfolded proteins. The findings open new
perspectives on repairing disrupted ER stress and cAMP signaling
in dystonia, in which torsinA may play a new key role.
Materials and Methods
Ethics Statement
All human cell lines and protocols in the present study were
carried out in accordance with the guidelines approved by
institutional review boards (IRB) at Partners Human Research
Committee (Protocol #: 2007P001632/MGH). Fibroblast cell
lines received from Dr. Xandra Breakefield laboratory were
previously collected through a Yale Medical School research
protocol between 1974–1984. Individuals enrolled in this research
protocol had skin biopsies taken, and signed consent forms. All
animal study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Massachusetts General Hospital
(MGH) Institutional Animal Care and Use Committee (IACUC)
(Protocol Number: 2004N000271/MGH). All surgery was per-
formed under anesthesia, and all efforts were made to minimize
suffering.
Animals
Heterozygous Tor1A knockout mice (Tor1A
+/2) [9], and
Heterozygous Tor1A knock-in mice (Tor1A
wt/DE) [7,9] were
received from Dr. Yuqing Li (University of Florida, Gainesville,
FL, USA). We crossed Tor1A
+/2 and Tor1A
wt/DE mice to
generate timed pregnancies. The day of vaginal plug detection was
considered embryonic day 0 (E0). Embryonic neuron cultures
were prepared from each embryo on embryonic day 15 (E15). The
genotype of each embryo was identified as reported previously
[7,9].
Mixed cortical and striatal neuron culture
Mixed cortical and striatal neuron cultures were prepared from
invidual E15 mouse embryos. Briefly, embryos were removed by
Caesarean section from a pregnant mouse. Cortices and striata
from embryonic mice were dissected and stored in ice-cold 1 x
phosphate buffered saline (PBS). The cortices and striata of
individual embryos were dissociated with 0.625% trypsin at 37uC
in neurobasal media (NBM, supplemented with B27, N2, 500 mg/
ml streptomycin, 100 IU/ml penicillin and 2 mM L-glutamine, all
from Invitrogen, Carlsbad, CA, USA). Trypsin was removed and
Dulbecco’s Modified Eagle Medium plus nutrient mix F12
(DMEM/F12, Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Invitrogen), N2 supplement and penicillin/strepto-
mycin added to inactivate the trypsin. Cortices and striata were
treated with 12.5 mg/ml DNase I (Sigma, St. Louis, MO, USA) in
DMEM/F12+ FBS for 5 min at 37uC and homogenized. Cell
suspension was then diluted in NBM supplemented with with B27,
0.5 mM L-glutamine. The cells were counted and then plated on a
96-well plate coated with polyethyleneimine (Sigma, St. Louis,
MO, USA) in 0.15 M Borate Buffer at a density of 4610
4 cells/
well. For each embryo, we generated approximately 8 wells. Half
the media was replaced with fresh media every two days. The cells
were treated with 5 mM cytosine arabinoside (ARA-C) four days
after being plated and the total media was changed after 24 hours.
The density of immunoreactive cells positive for bIII tubulin (a
neuronal marker), and GFAP (a marker of astrocytes) was
performed in parallel at 5–8 days in vitro (DIV). Results showed
that the majority of cells (99.5%) were positive only for bIII
tubulin. Note that cultures from individual neurons (an average of
10 well in 96 plates per embryos) were maintained for 10 days, and
were then used for cAMP assay.
Mouse embryonic fibroblast cells (MEFs)
MEF cultures were prepared as described [12,41] from single
embryos (embryonic day 15) of mating between heterozygous
torsinA knockout mice or torsinA knock-in mice. Cells were grown
in DMEM (GIBCO, Rockville, MD) as described [41]. MEFs cells
were seeded, and incubated overnight before the cAMP assay.
Human fibroblast cell culture
Primary human skin fibroblasts of control fibroblasts (HF6,
HF19) and of DYT1 patient’s fibroblast (HF48) were generated in
Dr. Breakefield ‘s laboratory as described previously [42], under
IRB approved guidelines. Fibroblast control cell lines GM00023,
GM00024, GM01651, GM02912, and DYT1 patient fibroblast
cell lines GM02551, GM03208, GM032011, GM02306 were
purchased from Coriell Institute for Medical Research (Camden,
NJ). The Coriell Cell Repository maintains the consent and
privacy of the donor fibroblast samples. DYT1 patient fibroblast
cells, FFF13111983 [43], were provided from Dr. Mirella
Filocamo (Biobank from Patients affected by Genetic Diseases,
L’Istituto Giannina Gaslini, Genoa, Italy), a member of the
Telethon Network of Genetic Biobanks (project no. GTB12001).
The primary fibroblast cells were grown in culture, as described
[24]. For more information about the human fibroblast cell lines,
see Table S1. Human fibroblast cells were seeded, and incubated
overnight before the cAMP assay.
Western blot
SDS-PAGE electrophoresis and protein transfer were carried
out as described [23]. Membranes were probed with antibodies
against b-actin (1:5,000), and mouse torsinA (1:1000) (Abcam)
diluted in TBST and visualized with HRP conjugated to
secondary antibodies and SuperSignal West Pico Chemilumines-
cent Substrate (Pierce). Secondary antibodies for Western blots
were sheep anti-mouse IgG-HRP (1:10,000) or donkey anti-rabbit
Dystonia in ER Stress and cAMP Signaling
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NJ).
Chemicals
Forskolin (Sigma, St. Louis, MO, USA) was dissolved in DMSO
at 10 mM concentration. Thapsigargin (Sigma, St. Louis, MO,
USA) was suspended in DMSO at 3 mM. The phenylbutyric acid
or 4-phenylbutyrate (4-PBA; Sigma, St. Louis, MO, USA) was
dissolved in filtered sterile water at a 1 M stock concentration.
cAMP ELISA Assay
We have optimized an ELISA cAMP assay (GE Healthcare) to
determine cAMP intracellular levels in dystonia cell models.
Briefly, neuron cells were seeded in a 4610
4 cells/well (neurons)
and 5610
3 cells/well (fibroblasts) in 96-well plates. Fibrolast cells
were incubated overnight before the assay, and neurons were
culture for 10 days prior to the assay. After 30 minutes incubation
with or without 10 mM forskolin, the cAMP levels were
determined according to the manufacture’s instructions. At least
three independent experiments were performed for each assay.
Data were normalized to the amount of protein in each sample, as
determined using a dye-binding protein assay (Bio-Rad).
ATP/Cell viability analysis
Neuronal and fibroblast viability was evaluated by CellTiter-
Glo luminescent cell viability assay (Promega, Madison, WI) to
determine the number of viable cells in culture based on the
quantitation of ATP levels, indicating the presence of metaboli-
cally active cells. Briefly, primary neurons and fibroblast cells were
grown as described above and a volume of CellTiter-Glo Reagent
was added to each well equal to the volume of cell culture
medium. Then, the contents were mixed for 2 min on a shaker to
induce cell lysis and the plates were incubated at room
temperature for 10 min in the dark. Cellular luminescence
intensity was measured using a Luminometer (Dynex Technolo-
gies, Chantilly, VA).
Quantitative real-time qPCR
Total RNA of cells was extracted with RNeasy mini kit (Qiagen,
Valencia, CA). The cDNA was prepared from total RNA using
Superscript first-strand synthesis system (Invitrogen) with the oligo
(dT)
12–18 primers, according to the manufacturer’s instructions.
RNA samples were treated with DNase I (Invitrogen) for the
elimination of genomic DNA. Human spliced form of XBP1
mRNA expression (forward: 59-AACCAGGAGTTAAGA-
CAGCGCTT-39, reverse: 59-CTGCACCCTCTGCGGACT-39)
was determined by real-time qPCR using relative quantitation by
the comparative threshold cycle number (Ct) method, iCycler, and
SYBR Green Ready-mix (Bio-Rad, Hercules, CA) and normalized
by glyraldehyde-3-phosphate dehydrogenase (GAPDH) expres-
sion. Preliminary experiments were performed with each primer
pair to determine the amplification temperature that provided an
optimal correlation between template concentration and signal
intensity. At least three independent experiments were performed
for each assay.
Data analysis and statistics
Statistical analysis was performed using GraphPad Prism
software (version 3.0). Results are expressed as mean 6 S.E.M.
of at least three separate experiments unless otherwise indicated.
Statistical significance of comparison between two groups was
determined by two-tailed Student’s t-test where indicated.
Multiple comparison analyses of variance between the groups
were performed by a one-way ANOVA test, followed by a Tukey’s
multiple comparison post hoc tests. Significant differences were
considered at p values of less than 0.05.
Results
Abnormal torsinA function downregulates cAMP
production in dystonia mice and human cell models
We first observed a potential relationship between mutant
torsinA and adenylate cyclase during our studies using cholera
toxin to examine the role torsinA might play in ERAD [24]. We
found that cAMP levels in cell lines expressing mutant torsinA
were lower after treatment with cholera toxin, a well known cAMP
agonist, when compared to control cell lines.
Thus, to test the hypothesis that torsinA status might affect
agonist-induced adenylate cyclase activities, we examined cAMP
production in several dystonia models using forskolin, which is a
general and direct activator of the adenylate cyclases. We first
demonstrated complete lack of torsinA expression in torsinA
knockout model (Figure 1A). Then, we investigated the forskolin-
induced cAMP response in wild-type (torsinA
+/+), and homozy-
gous (torsinA




-/- neurons from knockout dystonia mice
(Figure 1C). Results showed a strong loss of cAMP signal in
torsinA
-/- MEFS (n=3; p,0.001; Figure 1B), and in torsinA
-/-
neurons (n=3; p,0.01; Figure 1C) compared to wild-type
controls upon stimulation of the cells with forskolin. Similar
results were obtained in primary neuron cultures from torsinA
knock-in mice (Figure 1D). The presence of torsinADEi n
heterozygous and homozygous neurons led to lower levels of
cAMP (n=3; p,0.05; Figure 1D), when compared to controls.
Furthermore, we confirmed that the inhibition of forskolin-
induced cAMP production in cells lacking torsinA or expressing
mutant torsinA, torsinADE, were not due to a reduction of
intracellular levels of ATP in our DYT1 dystonia models, which
could have confounded our results (Figure 1E, and 1F). There
were no significant differences in the ATP levels measured in this
study between wild type cells and cells from knockout (Figure 1E)
or knock-in mice (Figure 1F).
To test whether these results translate to human cell models, we
investigated whether cAMP levels were also altered in human
fibroblast lines prepared from various dystonia DYT1 patients and
healthy controls. At rest, there was no overall difference between
control and DYT1 fibroblasts in basal levels of intracellular cAMP
(Figure 2A). After forskolin stimulation, however, the induction of
cAMP levels in DYT1 cells was significantly lower compared to
control cells (n=3; p,0.05; Figure 2A). One of the control cell
lines, GM00023B, presented the lowest cAMP response to
forskolin among control cell lines, and comparable in magnitude
to the signals observed in DYT1 fibroblasts. However, we also
observed that the GM00023B cells also presented the lowest basal
level of cAMP, suggesting a general lower activity of adenylate
cyclase in this specific line. Thus, to control for this, the cAMP
levels induced by forskolin were normalized to the basal level of
cAMP for each cell line and represented again by fold change after
forskolin treatment. When the data was normalized to cell basal
levels, all fibroblasts from healthy patients had uniformly increased
responses to forskolin stimulation compared to all DYT1 fibroblast
lines (n=3; p,0.001; Figure 2B).
4-PBA, an ER stress inhibitor, rescues ER stress and cAMP
defects in DYT1 patient fibroblasts
We previously reported that the absence of torsinA or the
presence of malfunctioned torsinADE induces ER stress [23,24].
Dystonia in ER Stress and cAMP Signaling
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fibroblast cells by quantitative real-time PCR (qPCR) of the
spliced form of the transcription factor X-box binding protein 1
(sXBP1). Our results show that DYT1 fibroblasts induced more
XBP1 splicing (Figure 3) in both unstimulated (DMSO treatment),
and stimulated (Thapsigargin treatment) conditions compared to
control cells. Also we confirmed that neurons expressing
torsinADE have higher levels of sXBP1 compared to control
neurons (Figure S1) in unstimulated conditions. This suggests that
the presence of torsinADE enhances ER stress.
Furthermore, we investigated whether 4-PBA, a small molecule
with chaperone-like activity, may decrease ER stress in our
dystonia cell models. 4-PBA major function is to scavenge
ammonia and glutamine [44], however, recent studies have
described 4-PBA as a potent inhibitor of HDAC [45], and function
as a chemical chaperone during ER stress [46]. Rubenstein et al.
first discovered the chaperone-like activity of 4-PBA when
examining its effect on the trafficking of CFTRDF508 to the cell
surface [47]. In ER stress, 4-PBA may improve mislocalization,
Figure 1. Absence of torsinA or presence of torsinADE, downregulates cAMP production in dystonia animal models. (A) Lysates from
mouse embryonic fibroblasts (MEFs) cells from controls (torsinA
+/+) and MEFs from knockout torsinA mice (torsinA
-/-) were resolved by SDS-PAGE, and
immunoblotted with antibodies specific to mouse torsinA (torsinA), and b-Actin, showing the absence of torsinA in torsinA
-/- MEFs. (B) To analyze
differences in cAMP levels in torsinA
+/+, and torsinA
-/- MEFs, the cAMP production was measured under basal conditions and in response to the direct
adenylate cyclase agonist forskolin (10 mM). Although no significant differences in basal cAMP production were observed in MEFs cells, there was a 5-
fold reduction (***P,0.001; Student t-test, n=3 experiments) in torsinA
-/- MEFs after forskolin stimulation compared to control torsinA
+/+ MEFs. (C)
Primary mixed cortical and striatal neuronal cultures of individual E15 embryos from controls littermates (torsinA
+/+), heterozigous Knockout torsinA
(torsinA
+/-), and homozigous Knockout torsinA (torsinA
-/-). No signicant differences in basal cAMP production were observed, however a 1.5 fold
reduction of cAMP levels was also observed in torsinA
-/- neurons (**P,0.01; Student t-test, n=3 experiments) after forskolin stimulation compared to
control torsinA
+/+, neurons. (D) Same results were found in knock-in dystonia models. A 1.2 fold reduction in the cAMP production was obseved in
heterozygotes Knock-in (torsinA
WT/DE) neurons (*P,0.05; one-way ANOVA and Tukey’s post hoc comparison, n=3 experiments), and a 1.4 fold
reduction in homozygotes Knock-in (torsinA
DE/DE) neurons (*P,0.05; one-way ANOVA and Tukey’s post hoc comparison, n=3 experiments) in
forskolin-stimulated cAMP production cells compared to control torsinA
wt/wt neurons. (D) Since adenylate cyclase catalyzes the conversion of ATP to
cAMP, intracellular ATP levels were measured from torsinA
-/- MEFs and control torsinA
+/+ MEFs (E), and in heterozygous or homozygous Knock-in
neurons (F), when compared to controls. The intracellular ATP levels were determined from cell lysates using the ATP-Glo
TM Bioluminometric Cell
Viability Assay. No significant differences were found in the ATP levels (n=3 experiments).
doi:10.1371/journal.pone.0110086.g001
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human disease [48].
In parallel experiments, gradual titrations of 4-PBA (2.5, 5, 10,
15 mM, 20 mM) were performed to assess the effects of PBA on
ER stress in health fibroblast cells, and in DYT1 fibroblast cells.
We observed, however, that treatment with concentrations 2.5 and
5 mM did not affect ER stress in health fibroblast cells, or in
DYT1 fibroblast cells (Figure 3A). However, the treatment with
10 mM 4-PBA abrogated the thapsigargin response in DYT1
patient fibroblast cells (n=3; p,0.001; Figure 3B), but had no
effect on the response to thapsigargin in healthy fibroblast cells. In
contrast, higher concentrations 15 and 20 mM 4-PBA were toxic
for both cell types (data not shown). This result suggests that
reduced chaperone function in cells expressing torsinADE may be
responsible for increased ER stress. Since impaired expression of
G protein coupled receptors (GPCRs) may be responsible for
deficits in the cAMP/PKA signaling, we assessed whether
mitigation of ER stress with 4-PBA could rescue the cAMP
defects of DYT1 fibroblast cells (Figure 4A). We observed that the
treatment with 4-PBA enhanced the cAMP response to forskolin in
DYT1 patient fibroblast cells, with signals comparable to control
cell lines (n=3; p,0.05; Figure 4A). We note that pretreatment of
4-PBA reducing ER stress did not affect the forskolin-stimulated
cAMP level in the control cell lines (Figure 4A), suggesting that 4-
PBA had effects only on cells expressing mutant torsinA. Thus, 4-
PBA appears to rescue both ER stress and cAMP accumulation in
DYT1 fibroblast cells. In addition, we observed no significant
changes in ATP levels measured in this study between healthy
fibroblast cells and DYT1 patient fibroblast cells (Figure 4B).
Discussion
Here, we addressed the involvement of torsinA in the response
to ER stress and to the cAMP pathways. How these two pathways
are linked mechanistically remains unclear, but it is possible
though that the ER stress induced by mutant torsinA in patients
with DYT1 dystonia contributes to neuronal dysfunction through
a cAMP defect (Figure 5). In our previous studies on the torsinA-
related AAA-ATPase p97, which also operates in ERAD and
induces ER stress upon dysfunction, we found an inhibitory effect
on adenylate cyclase when p97 was mutated [49]. Remarkably, we
Figure 2. Adenylate Cyclase (AC) activity is reduced in DYT1 dystonia patient fibroblast cells. (A) A 2.5-fold reduction (*P,0.05; one-way
ANOVA and Tukey’s post hoc comparison, n=3 experiments) in the cAMP accumulation was observed by DYT1 patient fibroblast cell lines (6 cell lines
represented in black 7–12: GM02306, GM02551, GM3208, GM03211, FFF13111983, HF48) compared to healthy fibroblast cell lines (6 cell lines
represented in white 1–6: GM00023, GM00024, GM01651, GM02902, HF6, HF19) in response to forskolin (10 mM). The line GM00023 from a healthy
subject (1) showed no significant increase when compared to DYT1 patient fibroblast lines. (B) Results are also expressed as fold increase over basal
cAMP level of each cell line. All DYT1 fibroblast lines have decreased response to forskolin stimulation compared to healthy fibroblast cells, including
GM00023 (**P,0.01; one-way ANOVA and Tukey’s post hoc comparison, n=3 experiments).
doi:10.1371/journal.pone.0110086.g002
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caused by torsinA mutants and this is associated with rescue of the
forskolin-induced cAMP-response. We propose that 4-PBA might
have therapeutic benefits in patients with dystonia.
Defective proteasome function and ER stress have a contrib-
uting role in various neurologic diseases [50]. In response to stress,
cells temporarily decrease protein synthesis, delay membrane
trafficking, increase movement of unfolded proteins out of the ER
into the cytoplasm via ERAD, and up-regulate transcription of
some chaperone proteins [51]. Recently, our group has shown an
aberrant regulation of proteasome activity in dystonia [24].
Protein components of the ERAD pathway, for example, p97
and Derlin-1, as well as torsinA, have been found in inclusion
bodies in brain and peripheral nerves from patients with a variety
of neurodegenerative diseases, as well as dystonia [52–55].
Additionally, complementary evidence indicates that torsinA can
reduce ER stress caused by ER protein overload in nematodes,
and that torsinA deficient MEFs have increased levels of ER stress,
as compared with wild-type MEFs [23,24]. Interestingly, it has
been proposed that ER stress can cause down-regulation of cAMP
production in diabetes [56], and that a cAMP elevating reagent
(CGS21680, an adenosine A2 receptor agonist) enhances protea-
some activity in synapses of the striatum of R6/2 Huntington
mouse model [57]. Interestingly, it has been shown that the
proteasome activity can be regulated by PKA [58]. Future studies
are needed to determine whether the impairment of proteasome
activity in cells expressing torsinADE may cause accumulation of
PKA regulatory subunits and/or suppression of PKA activity.
Our findings linking ER stress and cAMP signaling in dystonia
models, also highlights that there is much to consider about striatal
Figure 3. 4-PBA alleviates ER stress in dystonia models. (A) Healthy control fibroblast cells lines (average of 3 lines: HF6, HF19 and GM02912)
and DYT1 patient fibroblast lines (average of three lines: GM02306, GM02551 and GM03211) were treated for 18 hours in the absence or presence of
2.5 or 5 mM concentrations of 4-PBA, then challenged or not with 1 mM thapsigargin (Thaps.) for 3 hours. We have not observed significant
differences in sliced XBP1 (sXBP1) levels, an ER stress marker, upon 4-PBA treatments (2.5 and 5 mM) in healthy control or DYT1 fibroblast cells. (B) As
shown in (A), healthy fibroblast cells lines (3 lines represented in white 1–3: HF6, HF19, and GM02912) and DYT1 patient fibroblast cell lines (3 lines
represented in black 4–6: GM02306, GM02551, and GM03211) were treated for 18 hours in the absence or presence of 10 mM concentration of 4-
PBA, then challenged or not with 1 mM thapsigargin (Thaps.) for 3 hours. DYT1 fibroblasts cell lines have increased levels of mRNA expression levels
of sliced XBP1 (sXBP1), an ER stress marker, compared to healthy controls (**P,0.01; one-way ANOVA and Tukey’s post hoc comparison, n=3
experiments) when stimulated with thapsigargin. However, when DYT1 fibroblast cells were pre-treated with 10 mM 4-PBA, they showed reduced
sXBP1 levels, similar to healthy control lines. A 1.2 reduction in the sXBP levels was observed when DYT1 fibroblast cells challenged with thapsigargin,
and treated with 4-PBA (**P,0.01; one-way ANOVA and Tukey’s post hoc comparison, n=3 experiments). The results indicate that the presence of
torsinADE induces ER stress in fibroblast cells, however, 10 mM 4-PBA treatment decreases ER stress in DYT1 patient lines.
doi:10.1371/journal.pone.0110086.g003
Dystonia in ER Stress and cAMP Signaling
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e110086signaling to cAMP and PKA. Benzodiazepines are frequently used
in the treatment of dystonia. This drug has muscle-relaxant
properties and alleviates pain caused by muscle spasms and
various dystonias [59,60]. Interestingly, the administration of
diazepam, a benzodiazepine anxiolytic, in rhesus monkeys, is
known to increase cAMP by inhibiting PDE cAMP hydrolysis
[61].
Figure 4. cAMP defects in dystonia models are rescued by 4-PBA treatments. (A) Healthy control fibroblast cells (3 lines represented in
white 1–3: HF6, GM01651, and GM02912) and DYT1 patient fibroblast cells (3 lines represented in black 4–5: GM02306, GM02551, and GM03211) were
pre-treated with or without 4-PBA for 18 hours, followed by 10 mM forskolin stimulation for 30 minutes. As observed previously, DYT1 fibroblast lines
have significantly lower levels of cAMP accumulation after forskolin stimulation compared to healthy control fibroblast lines (**P,0.01; one-way
ANOVA and Tukey’s post hoc comparison, n=3 experiments). However, the 4-PBA treatments also significantly rescued cAMP accumulation
deficiency in DYT1 patient fibroblast lines comparable to control fibroblasts cAMP levels (*P,0.5; one-way ANOVA and Tukey’s post hoc comparison,
n=3 experiments). (B) No significant changes were observed in the intracellular ATP levels from healthy control cells (HF6, GM01651, GM02912) and
DYT1 fibroblast cells (GM2306, GM02551, GM3211).
doi:10.1371/journal.pone.0110086.g004
Figure 5. Model of torsinA modulation of cAMP. In healthy fibroblast cells (left panel), forskolin stimulates adenylate cyclase (AC) to synthesis
cAMP, and there is no presence of Endoplasmic Reticulum (ER) stress in normal conditions. In absence of torsinA or in presence of mutant torsinA,
torsinADE (right panel), cells present increased ER stress and lower cAMP accumulation. However, 4-PBA treatment rescues both ER stress and cAMP
accumulation defects in DYT1 dystonia cell models by unoknow mechanism (s).
doi:10.1371/journal.pone.0110086.g005
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PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e110086Numerous lines of evidence have linked dopaminergic dysfunc-
tion to dystonia [4,5]. The physiological actions of dopamine are
mediated by five distinct but closely related G protein-coupled
receptors (GPCRs) that are divided into two major groups: the D1
(D1, D5) and D2 (D2, D3. D4) classes of dopamine receptors [62].
The D2 class is coupled to inhibitory G-proteins (G0/i) that
decrease adenylate cyclase activity and cAMP levels, in contrast to
the D1 class which acts through stimulatory G-proteins (e.g. Gsa)
to increase activity and cAMP levels [63]. Dystonia has been
associated with mutations in genes encoding proteins critical for
dopamine (DA) signaling, such as GTP-cyclohydrolase [34],
tyrosine hydroxylase [35], as well as polymorphisms in the DA
receptor subtype, D5R [64], and GNAL dystonia gene, which
encodes G a olf, a central component for striatal responses to
dopamine (DA) [36]. Furthermore, several imaging studies showed
various DA-related abnormalities, such as altered receptor binding
in basal ganglia, in patients with different forms of dystonia [65–
67]. Interestingly, it has been shown that adenylate cyclase
activation by forskolin is highly potentiated in the presence of
stimulatory G-proteins, such as G a olf [68]. Mutations in GNAL
remove essential functional regions of Gaolf, responsible for
activation of the G protein receptor D1 and Adenosine Receptor
A2 (A2R), affecting cAMP accumulation. Thus, it is possible that
mutations in GNAL and TOR1A genes may lead to dystonia via a
common mechanism related to cAMP signaling. Perhaps torsinA
participates in the proper folding/oligomerization of GPCR, or
stimulatory G-proteins, reducing the function of these proteins.
Our results suggest that 4-PBA may have clinical utility in the
treatment of dystonia. 4-PBA is a low molecular weight fatty acid
already approved for clinical use as an ammonia scavenger in
children with urea cycle disorders [69]. Several groups revealed
that 4-PBA reverses the mislocalization and/or aggregation of the
protein associated with human disease, including the DF508 cystic
fibrosis transmembrane conductance regulator [47], mutant a1-
antitrypsin [70]. In addition, 4-PBA improves the trafficking of the
serotonin transporter (SERT) [71], by reversing the misfolded
proteins and decreasing the protein folding load in the ER,
therefore providing protective effects against ER stress. A previous
study has shown that 4-PBA treatment decreases ER stress with
regard to the following general ER stress markers: BiP, CHOP,
activating transcription factor 4 (ATF4), as well as sXBP1 [56].
Additionally, 4-PBA alleviates ER stress by the Pael receptor,
which is thought to be accumulated in PARK2, one type of
inherited Parkinson’s disease [72], reduced the area of damage due
to ischemia in a rat model of cerebral infarction [73], it has been
found to prolong life [74], and contribute to therapy for spinal
muscular atrophy [75] by altering the pattern of gene expression.
4-PBA has high potential to treat neurologic diseases because it
penetrates the blood–brain barrier, and exhibits significant
neuroprotective effects in mouse models of neurodegenerative
diseases, such as Alzheimer’s disease (AD) [76], and Parkinson’s
disease (PD) [77]. As described above 4-PBA has multiple
applications. It can be explained by the fact that 4-PBA has also
multiple functions. First, 4-PBA may act as a chemical chaperone
preventing the mislocalization and/or aggregation of proteins
associated with human disease. Second, 4-PBA also possesses
histone deacetylase (HDAC)-inhibitor activity. Initially HDAC
inhibitors were designed as anti-cancer agents because of their
important roles in the epigenetic regulation of protein translation.
Recently, HDAC inhibitors have been implicated in the treatment
of many neurodegenerative diseases [78]. Furthermore, the
HDAC inhibitory function of 4-PBA has also been studied in
neurodegenerative diseases related to abnormal histone acetyla-
tion, such as Huntington’s disease (HD) [79], amyotrophic lateral
sclerosis (ALS) [80], and spinal muscular atrophy (SMA) [75].
The precise steps by which mutant torsinA leads to impaired
cAMP accumulation are not known, but it may involve an ER
dysfunction. Further studies are needed to test this hypothesis, and
to determine the efficacy of treatment of DYT1 dystonia that
targets both ER stress and cAMP cascade. More studies are also
needed to elucidate whether 4-PBA is functioning as a HDAC
inhibitor or as a molecular chaperone in our dystonia cell models.
This will provide insightful information for the structural
optimization of this compound. Nevertheless, therapies working
through the ER stress and cAMP cascade in the striatum may have
the potential to benefit dystonia patients by alleviating dystonic
symptoms. Animal studies will determine whether 4-PBA can be
used to treat, as well as prevent, DYT1 dystonia.
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Figure S1 Neurons expressing torsinADE has higher ER stress
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